BioPharmSignal logoBioPharmSignal

Biotech News

Immuneering to Participate in Upcoming Investor Conferences

Immuneering (IMRX)ImmuneeringCompany update

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor

Related news

IMRXImmuneering2026-09-10 11:30 EST

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

IMRXImmuneering2026-08-26 21:16 EST

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

BMEABiomea Fusion2026-09-03 12:00 EST

Biomea Fusion to Participate in Upcoming Investor Conferences

ZNTLZentalis2026-09-02 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

RLAYRelay Therapeutics2026-09-01 20:46 EST

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

MMSIMerit Medical2026-09-04 13:25 EST

Merit Medical to Participate in Upcoming Investors Conferences in September

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

View all latest news

Immuneering

Deep Cyclic Inhibitors Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity. Atebimetinib Atebimetinib is an oral, once-daily...

Recent company news

IMRXImmuneering2026-09-10 11:30 EST

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival

IMRXImmuneering2026-09-03 20:05 EST

Immuneering to Participate in Upcoming Investor Conferences

IMRXImmuneering2026-08-26 21:16 EST

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

IMRXImmuneering2026-08-05 11:30 EST

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates

IMRXImmuneering2026-07-21 20:05 EST

Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

Stock data

Close
4.46 USD
Market cap
276.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States